EFMC-ISMC 2012

22nd International Symposium on Medicinal Chemistry

 Berlin, Germany    September 2-6, 2012

Committees


International Organising Committee

Symposium Chairmen

  • B. CLEMENT (Kiel University, Kiel, Germany)
  • E. OTTOW (Bayer HealthCare, Berlin, Germany)

Members

  • K. AUGUSTYNS (University of Antwerp, Antwerp, Belgium)
  • R. P. CLAUSEN (University of Copenhagen)
  • E. DIFFERDING (Differding Consulting, Louvain-la-Neuve, Belgium)
  • R. MOREIRA (University of Lisbon, Lisbon, Portugal)
  • H. TIMMERMAN (VU University Amsterdam, Oegstgeest, The Netherlands)

Local Organising Committee

Members

  • K.-H. ALTMANN (ETH Zurich, Zurich, Switzerland)
  • A. BUSCHAUER (University of Regensburg, Regensburg, Germany)
  • P. GMEINER (Friedrich Alexander University, Erlangen, Germany)
  • R. HAAG (Free University Berlin, Berlin, Germany)
  • M. KALESSE (University of Hannover, Hannover, Germany)
  • S. LAUFER (University of Tübingen, Tübingen, Germany)
  • J. MACK (Boehringer Ingelheim, Biberach an der Riss, Germany)
  • H. P. MAERKI (F. Hoffmann-La Roche, Basel, Switzerland)
  • P. H. SEEBERGER (Max Planck Institute of Colloids and Interfaces, Berlin, Germany)
  • O. SEITZ (Humboldt University Berlin, Berlin, Germany)
  • H. U. STILZ (Novo Nordisk, Malov, Denmark)
  • R. D. SÜSSMUTH (Technical University Berlin, Berlin, Germany)
  • H. WALDMANN (Max Planck Institute of Molecular Physiology, Dortmund, Germany)
  • H. WEINMANN (Bayer Pharma, Berlin, Germany)

International Scientific Committee

Members

  • M. D. ANDREWS (Pfizer, Sandwich, United Kingdom)
  • P. ARTURSON (University of Uppsala, Uppsala, Sweden)
  • S. O. BACHURIN (Institute of Physiologically Active Compounds, Chernogolovka, Russia)
  • E. BANOGLU (Gazi University, Ankara, Turkey)
  • M. BRANDS (Bayer Pharma AG, Wuppertal, Germany)
  • T. CARELL (Ludwig-Maximilians-University Munich, Munich, Germany)
  • N. CARRUTHERS (Johnson & Johnson R&D, San Diego, United States)
  • G. CRISTALLI (University of Camerino, Camerino, Italy)
  • F. DA SETTIMO (Università di Pisa, Pisa, Italy)
  • P. S. DA SILVA (Bial Ltd, S. Mamede do Coronado, Portugal)
  • A. M. DAVIS (AstraZeneca R&D, Loughborough, United Kingdom)
  • F. DENONNE (UCB Pharma, Braine-l'Alleud, Belgium)
  • G. DUBURS (Latvian Institute of Organic synthesis, Riga, Latvia)
  • G. ECKER (University of Vienna, Vienna, Austria)
  • P. ETTMAYER (Boehringer Ingelheim, Vienna, Austria)
  • J. FISCHER (Richter Plc, Budapest, Hungary)
  • C. GARCIA-ECHEVERRIA (Sanofi, Vitry sur Seine, France)
  • M. GASIC (Serbian Academy of Sciences and Art, Belgrade, Serbia)
  • G. GAVIRAGHI (Siena Biotech, Siena, Italy)
  • E. GILLAM (University Queensland, Brisbane, Australia)
  • M. HANN (GSK Medicines Research Centre, Stevenage, United Kingdom)
  • R. HARTMANN (Saarland University, Saarbruecken, Germany)
  • L. HENNEQUIN (AstraZeneca, Reims, France)
  • T. HOFFMANN (F. Hoffmann-La Roche, Basel, Switzerland)
  • U. HOLZGRABE (University of Wuerzburg, Wuerzburg, Germany)
  • K. KIEC-KONONOWICZ (Jagiellonian University, Krakow, Poland)
  • G. KLEBE (Philipps-University Marburg, Marburg, Germany)
  • A. KOUROUNAKIS (University of Athens, Athens, Greece)
  • J. LAU (Novo Nordisk, Maaloev, Denmark)
  • B. LESUR (Institut de Recherches Servier, Croissy-Sur-Seine, France)
  • R. LEURS (VU University Amsterdam, Amsterdam, The Netherlands)
  • M. L. LOPEZ-RODRIGUEZ (Complutense University of Madrid, Madrid, Spain)
  • D. MA (Shanghai Institute of Organic Chemistry, Shanghai, China)
  • I. MALNAR (Halmed, Zagreb, Croatia)
  • R. MECHOULAM (Hebrew University, Jerusalem, Israel)
  • L. MEERPOEL (Janssen R&D, Beerse, Belgium)
  • R. METTERNICH (F. Hoffmann-La Roche, Basel, Switzerland)
  • J. MINERS (Flinders University School of Medicine, Bedford Park, Australia)
  • M. MISSBACH (Novartis, Basel, Switzerland)
  • C. MÜLLER (University of Bonn, Bonn, Germany)
  • K. MÜLLER (F. Hoffmann-La Roche, Switzerland)
  • P. O'NEILL (University of Liverpool, Liverpool, United Kingdom)
  • D. OLIVER (North-West University, Potchefstroom, South Africa)
  • R. PELLICCIARI (University of Perugia, Corciano, Italy)
  • L. PETERLIN MASIC (University of Ljubljana, Ljubljana, Slovenia)
  • D. ROGNAN (CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France)
  • Y. ROLLAND (Société de Chimie Thérapeutique, Châtenay-Malabry, France)
  • M. ROWLEY (Merck Research Laboratories, Kriens, Switzerland)
  • F. SANZ (University Pompeu Fabra, Barcelona, Spain)
  • G. SCHNEIDER (ETH Zürich, Zurich, Switzerland)
  • G. SERRA (Udelar, Montevideo, Uruguay)
  • K. B. SIMONSEN (Lundbeck, Valby, Denmark)
  • G. TAMAGNAN (Institute for Neurodegenerative Disorders and Molecular NeuroImaging, LLC, New Haven, United States)
  • B. K. TRIVEDI (Wockhardt R&D, Aurangabad, India)
  • J. UETRECHT (University of Toronto, Toronto, Canada)
  • E. WALLEN (University of Helsinki, Helsinki, Finland)
  • H. WEINSTEIN (Cornell University, New York, United States)
  • R. WEXLER (Bristol-Myers Squibb, Princeton, United States)
  • J. WÖLFLING (University of Szeged, Szeged, Hungary)
  • A. YONATH (Weizmann Institute of Science, Rehovot, Israel)
  • L.-H. ZHANG (Beying Medical University, Beying, China)
  • M.-Q. ZHANG (Amgen China, Shanghai, China)